BRKR-JPM26-Presentation-Final.pdf

1、BRUKER 2026 ThemesAfter 70%Revenue Jump,our Focus is now on a Transformative Margin and EPS JumpExpanding our Leadership in Post-Genomic Discovery SolutionsProject Accelerate 3.0:adding Novel Diagnostics and Automated AI-Lab OpportunitiesFrank H.LaukienChairman,President&CEOBruker Corporation(Nasdaq

2、:BRKR)2026 JP Morgan Healthcare ConferenceSan Francisco,CA|January 12,2026INNOVATION WITH INTEGRITY|2023 Bruker|2025 Bruker|BRUKER CORPORATION Safe Harbor Statement2January 12,2026J.P.Morgan Healthcare ConferenceAny statements contained in this presentation which do not describe historical facts may

3、 constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,as amended,and Section 21E of the Securities Exchange Act of 1934,as amended,including statements regarding our preliminary fourth quarter and fiscal year ended December 31,2025 operational and fin

4、ancial performance,including our revenue growth,non-GAAP operating margin,non-GAAP EPS and non-GAAP tax rate;ROIC;EBITDA;managements expectations for future financial and operational performance,expected growth,and business outlook including the expected financial contributions of BSI and benefits o

5、f Project Accelerate,statements regarding our business focus,expected market growth and market size;and product performance.Any forward-looking statements contained herein are based on current expectations,but are subject to risks and uncertainties that could cause actual results to differ materiall

6、y from those indicated,including,but not limited to,risks and uncertainties relating to continued volatility in the capital markets,the impact of Project Accelerate,the performance of breakout opportunities,the integration and assumption of liabilities of businesses we have acquired or may acquire i